Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: An immunohistochemical study on 75 patients

Histopathology

Volumn 46, Issue 5, 2005, Pages 540-550

  Thiele, Juergen ^a   Kvasnicka, H M ^a   Schmitt Graeff, A ^a   Kriener, S ^a   Engels, K ^a   Staib, P ^a   Ollig, E S ^a   Keller, C ^a   Fokkema, S ^a   Griesshammer, M ^b   Waller, C F ^c   Ottmann, O G ^d   Hansmann, M L ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Apoptosis; Blasts; Bone marrow; Imatinib (STI571); Megakaryocytes; Myelofibrosis; Proliferation

Indexed keywords

CD34 ANTIGEN; CD61 ANTIGEN; CYCLINE; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; APOPTOSIS; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; ERYTHROID PRECURSOR CELL; FEMALE; GRANULOPOIESIS; HEMATOPOIESIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MORPHOMETRICS; MYELOBLAST; MYELOFIBROSIS; PRIORITY JOURNAL; STEM CELL; TREATMENT OUTCOME;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BIOPSY; BONE MARROW CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN BETA3; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PIPERAZINES; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TIME FACTORS;

EID: 20944448212     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02119.x     Document Type: Article

References (55)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96; 3343-3356.
2. Marley SB, Deininger MW, Davidson RJ, Goldman JM, Gordon MY. The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp. Hematol. 2000; 28; 551-557.
3. Oetzel C, Jonuleit T, Gotz A et al. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin. Cancer Res. 2000; 6; 1958-1968.
4. Mauro MJ, Druker BJ. STI571: targeting BCR-ABL as therapy for CML. Oncologist 2001; 6; 233-238.
5. Heinrich MC, Griffith DJ, Druker BJ et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96; 925-932.
6. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 2000; 105; 3-7.
7. O'Dwyer ME, Druker BJ. Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr. Opin. Oncol. 2000; 12; 594-597.
8. Burchert A, Wolfl S, Schmidt M et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2003; 101; 259-264.
9. Wu C, Neuberg D, Chillemi A et al. Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk. Lymphoma 2002; 43; 2281-2289.
10. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001; 344; 1031-1037.
11. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 2001; 344; 1038-1042.
12. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001; 98; 2039-2042.
13. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99; 1928-1937.
14. Braziel RM, Launder TM, Druker BJ et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 2002; 100; 435-441.
15. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2003; 348; 994-1004.
16. Cervantes F, Hernandez-Boluda JC, Steegmann JL et al. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. Haematologica 2003; 88; 1117-1122.
17. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 2002; 346; 645-652.
18. Beham-Schmid C, Apfelbeck U, Sill H et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 2002; 99; 381-383.
19. Hasserjian RP, Boecklin F, Parker S et al. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am. J. Clin. Pathol 2002; 117; 360-367.
20. Rumpel M, Friedrich T, Deininger MW. Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase. Blood 2003; 101; 4641-4643.
21. Prater JL, Tallman MS, Variakojis D et al. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status. Am. J. Clin. Pathol 2003; 119; 833-841.
22. Bueso-Ramos CE, Cortes J, Talpaz M et al. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer 2004; 101; 332-336.
23. Soligo D, Delia D, Oriani A et al. Identification of CD34+ cells in normal and pathological bone marrow biopsies by QBEND10 monoclonal antibody. Leukemia 1991; 5; 1026-1030.
24. Gatter KC, Cordell JL, Turley H et al. The immunohistological detection of platelets, megakaryocytes and thrombi in routinely processed specimens. Histopathology 1988; 13; 257-267.
25. Falini B, Flenghi L, Pileri S et al. PG-M1: a new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule. Am. J. Pathol. 1993; 142; 1359-1372.
26. Pinkus GS, Said JW. Profile of intracytoplasmic lysozyme in normal tissues, myeloproliferative disorders, hairy cell leukemia, and other pathologic processes. An immunoperoxidase study of paraffin sections and smears. Am. J. Pathol. 1977; 89; 351-366.
27. Thiele J, Kvasnicka HM, Fischer R. Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders - aids to diagnosis and classification. Ann. Hematol. 1999; 78; 495-506.
28. Cordell JL, Falini B, Erber WN et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J. Histochem. Cytochem. 1984; 32; 219-229.
29. Bauermeister DE. Quantitation of bone marrow reticulin - a normal range. Am. J. Clin. Pathol. 1971; 56; 24-31.
30. Thiele J, Kvasnicka HM, Werden C et al. Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk. Lymphoma 1996; 22; 303-317.
31. McCormick D, Hall PA. The complexities of proliferating cell nuclear antigen. Histopathology 1992; 21; 591-594.
32. Hall PA, Levison DA. Review: assessment of cell proliferation in histological material. J. Clin. Pathol. 1990; 43; 184-192.
33. Thiele J, Meuter RB, Titius RB, Zankovich R, Fischer R. Proliferating cell nuclear antigen expression by erythroid precursors in normal bone marrow, in reactive lesions and in polycythaemia rubra vera. Histopathology 1993; 22; 429-435.
34. Frankfurt OS, Krishan A. Identification of apoptotic cells by formamide-induced DNA denaturation in condensed chromatin. J. Histochem. Cytochem. 2001; 49; 369-378.
35. Frankfurt OS. Immunoassay for single-stranded DNA in apoptotic cells. Meth. Mol. Biol. 2004; 282; 85-102.
36. Thiele J, Titius BR, Kopsidis C, Fischer R. Atypical micromegakaryocytes, promegakaryoblasts and megakaryoblasts: a critical evaluation by immunohistochemistry, cytochemistry and morphometry of bone marrow trephines in chronic myeloid leukemia and myelodysplastic syndromes. Virchows Arch. B. Cell Pathol. Ind. Mol. Pathol. 1992; 62; 275-282.
37. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90; 3691-3698.
38. Fang G, Kim CN, Perkins CL et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000; 96; 2246-2253.
39. Gambacorti-Passerini C, le Coutre P, Mologni L et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells. Mol. Dis. 1997; 23; 380-394.
40. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996; 2; 561-566.
41. Buchdunger E, Cioffl CL. Law N et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 2000; 295; 139-145.
42. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293; 876-880.
43. Yang M, Khachigian LM, Hicks C, Chesterman CN, Chong BH. Identification of PDGF receptors on human megakaryocytes and megakaryocytic cell lines. Thromb. Haemost. 1997; 78; 892-896.
44. Kimura A, Nakata Y, Hyodo H, Kuramoto A, Satow Y. Platelet-derived growth factor expression in accelerated and blastic phase of chronic myelogenous leukaemia with myelofibrosis. Br. J. Haematol. 1994; 86; 303-307.
45. Le Bousse-Kerdiles MC, Martyre MC. Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia. Springer Semin. Immunopathol. 1999; 21; 491-508.
46. Bartl R, Frisch B, Wilmanns W. Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD). Eur. J. Haematol. 1993; 50; 41-52.
47. Georgii A, Buesche G, Kreft A. The histopathology of chronic myeloproliferative diseases. Baillieres Clin. Haematol. 1998; 11; 721-749.
48. Thiele J, Kvasnicka HM, Varus E et al. Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy - a fluorescence in-situ hybridization study. Leuk. Lymphoma 2004; 45; 1627-1631.
49. Holtz MS, Slovak ML, Zhang F et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002; 99; 3792-3800.
50. Holtz MS, Bhatia R. Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells. Leuk. Lymphoma 2004; 45; 237-245.
51. Graham SM, Jorgensen HG, Allan E et al. Primitive, quiescent. Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99; 319-325.
52. La Rosee P, Shen L, Stoffregen EP, Deininger M, Druker BJ. No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec). Hematol. J. 2003; 4; 413-419.
53. Shah NP, Nicoll JM, Nagar B et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2; 117-125.
54. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100; 1014-1018.
55. Campbell LJ, Patsouris C, Rayeroux KC et al. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet. Cytogenet. 2002; 139; 30-33.